Mon, Dec 22, 2014
A A A
Welcome Guest
Free Trial RSS
Get FREE trial access to our award winning publications
Industry Updates

Greenwich Global Hedge Fund Index loses ground in May -1.20%

Thursday, June 09, 2011
Opalesque Industry Update - Hedge funds showed pockets of strength in May, but overall lost ground reports the Greenwich Global Hedge Fund Index (“GGHFI”). The GGHFI shed 1.20% compared to global equity returns in the S&P 500 Total Return (-1.13%), MSCI World Equity (-2.45%), and FTSE 100 (-0.89%) equity indices. 36% of constituent funds in the GGHFI ended the month with gains.

“Market Neutral strategies demonstrated their worth in May,” notes Clint Binkley, Senior Vice President. “Economic uncertainty took its toll on equity markets and Directional strategies in general during the month but managers that were less beta sensitive came out ahead. We expect a growing number of funds to decrease their net exposure as a result of recent volatility.”

Hedge Fund Strategy Highlights

  • Long-Short Credit and Arbitrage funds post best returns on the month
  • Long-Short Equity funds decline less than 1%

  • Managed Futures funds suffer from equity and commodity retreat, fall 3.25%

  • Long-Short Credit and Distressed Securities funds lead hedge funds on year-to-date basis, up 5.03% and 4.24%, respectively

  • Developed Market funds less impacted from global sell off than Emerging Market funds; the Greenwich Composite Regional indices fall by 1.18% and 1.99%, respectively

(press release)

The GGHFI is one of the oldest benchmarks of the hedge fund universe. Final Strategy and Regional index results for May will be available in early July, once additional funds have submitted returns. Past performance and indices construction rules for all Greenwich Hedge Fund Indices may be viewed at www.greenwichai.com.

Full performance tables:Source

kb

What do you think?

   Use "anonymous" as my name    |   Alert me via email on new comments   |   
Today's Exclusives Today's Other Voices More Exclusives
Previous Opalesque Exclusives                                  
More Other Voices
Previous Other Voices                                               
Access Alternative Market Briefing


  • Top Forwarded
  • Top Tracked
  • Top Searched
  1. Investing - Big hedge funds win again on PetSmart, Riverbed, RBS sells real estate loans to hedge fund Cerberus, Talisman energy speculation: Which hedge funds could benefit?[more]

    Big hedge funds win again on PetSmart, Riverbed From CNBC.com: Another week, another set of wins for activist investors. On Sunday, pet supply retailer PetSmart agreed to the largest leveraged buyout of the year at $8.7 billion. Hedge fund firm JANA Partners had been pushing for a sale a

  2. Outlook - Hedge fund manager who remembers 1998 rout says prepare for pain, Bond guru Bill Gross predicts U.S. economic growth to dip to 2%[more]

    Hedge fund manager who remembers 1998 rout says prepare for pain From Bloomberg.com: Stephen Jen landed in Hong Kong in early January 1997 as Morgan Stanley’s newly minted exchange-rate strategist for Asia. He was soon working around the clock when investors began targeting the region’s

  3. Investing - Hedge funds get boost from healthcare in 2014, Paulson & Co takes stake in Salix on heels of inventory issues[more]

    Hedge funds get boost from healthcare in 2014 From Valuewalk.com: The healthcare sector started the year on a turbulent note, as stocks of many major biotechnology companies were battered. However, most of the players in this sector have bounced back. The BarclayHedge Healthcare & Biotec

  4. North America - Why Steve Cohen, Connecticut hedge fund billionaire, gives so much in New York[more]

    From Insidephilantrophy.com: Billionaire Steve Cohen was born in Great Neck, New York before attending Wharton, working on Wall Street and then founding SAC Capital Advisors in Connecticut. Though his company (Point72) and foundation are based in Connecticut, Cohen and Alexandra are deeply connected

  5. Investing - Soros buys a highly speculative biotech in the third quarter[more]

    From Fool.com: …The Soros Fund bought 25,000 shares of the struggling small-cap biopharma Aegerion Pharmaceuticals in the third quarter. For those of you who haven't heard of this name, suffice to say that this was a surprising buy in light of the company's recent problems and poor outlook going for